UNIGE document Professional Article - Review
previous document  unige:24173  next document
add to browser collection

When are pro-inflammatory cytokines SAFE in heart failure?

Lecour, Sandrine
Published in European Heart Journal. 2011, vol. 32, no. 6, p. 680-5
Abstract The cytokine hypothesis presently suggests that an excessive production of pro-inflammatory cytokines, such as tumour necrosis factor alpha (TNF) and interleukin 6 (IL6), contributes to the pathogenesis of heart failure. The concept, successfully proved in genetically modified animal models, failed to translate to humans. Recently, accumulation of apparently paradoxical experimental data demonstrates that, under certain conditions, production of pro-inflammatory cytokines can initiate the activation of a pro-survival cardioprotective signalling pathway. This novel path that involves the activation of a transcription factor, signal transducer and activator of transcription 3 (STAT3), has been termed the survival activating factor enhancement (SAFE) pathway. In this review, we will discuss whether targeting the SAFE pathway may be considered as a preventive and/or therapeutic measure for the treatment of heart failure.
Keywords AnimalsCardiotonic Agents/pharmacologyCytokines/metabolism/physiologyDisease Models, AnimalHeart Failure/etiology/prevention & control/therapyHumansInterleukin-6/metabolismMiceRatsReceptors, Cytokine/physiologySTAT3 Transcription Factor/metabolismSignal Transduction/physiologyTumor Necrosis Factors/metabolism
PMID: 21303780
Full text
Article (Published version) (236 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Lipoprotéines sériques (598)
(ISO format)
LECOUR, Sandrine, JAMES, Richard William. When are pro-inflammatory cytokines SAFE in heart failure?. In: European Heart Journal, 2011, vol. 32, n° 6, p. 680-5. https://archive-ouverte.unige.ch/unige:24173

221 hits

0 download


Deposited on : 2012-11-21

Export document
Format :
Citation style :